Dosing of antipsychotics in schizophrenia across the life-spectrum

Hiroyuki Uchida, David C. Mamo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Age effects on dosing of antipsychotics in schizophrenia and mechanisms underlying those effects have not been well understood. The objective of this article is to review the literature regarding effects of age on antipsychotic dosing in schizophrenia and potential mechanisms underlying the age-related antipsychotic sensitivity. According to prescription surveys, age appears to have biphasic effects on prescribed antipsychotic dose. The dose increased with age through the third decade, subsequently plateaued, and decreased after the fifth decade. The first half of this inverted U-shaped relationship may be attributable to a deterioration process in the early phase of schizophrenia and the contribution of 'tachyphylaxis' of antipsychotics on the dopaminergic system. The following age-related decline in prescribed dose is likely associated with physiological aging. Recent data suggest that this increased antipsychotic sensitivity with age comes from age-related functional decline in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Although the evidence on potential mechanisms underlying age effects on antipsychotic dosing is still limited, alterations in the dopaminergic system due to aging and chronic exposure to this drug may contribute to the inverted U-shaped relationship between dose and age. This age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients age to enhance therapeutic effects as well as minimize their side effects.

Original languageEnglish
Pages (from-to)917-920
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume33
Issue number6
DOIs
Publication statusPublished - 2009 Aug 31
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Tachyphylaxis
Dopamine Receptors
Therapeutic Uses
Prescriptions
Dopamine
Pharmaceutical Preparations

Keywords

  • Aging
  • Antipsychotic
  • Dopamine
  • Elderly
  • Side effect

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Dosing of antipsychotics in schizophrenia across the life-spectrum. / Uchida, Hiroyuki; Mamo, David C.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 33, No. 6, 31.08.2009, p. 917-920.

Research output: Contribution to journalArticle

@article{2f3515cd0e5b43a6af3d9bbdaeeae43e,
title = "Dosing of antipsychotics in schizophrenia across the life-spectrum",
abstract = "Age effects on dosing of antipsychotics in schizophrenia and mechanisms underlying those effects have not been well understood. The objective of this article is to review the literature regarding effects of age on antipsychotic dosing in schizophrenia and potential mechanisms underlying the age-related antipsychotic sensitivity. According to prescription surveys, age appears to have biphasic effects on prescribed antipsychotic dose. The dose increased with age through the third decade, subsequently plateaued, and decreased after the fifth decade. The first half of this inverted U-shaped relationship may be attributable to a deterioration process in the early phase of schizophrenia and the contribution of 'tachyphylaxis' of antipsychotics on the dopaminergic system. The following age-related decline in prescribed dose is likely associated with physiological aging. Recent data suggest that this increased antipsychotic sensitivity with age comes from age-related functional decline in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Although the evidence on potential mechanisms underlying age effects on antipsychotic dosing is still limited, alterations in the dopaminergic system due to aging and chronic exposure to this drug may contribute to the inverted U-shaped relationship between dose and age. This age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients age to enhance therapeutic effects as well as minimize their side effects.",
keywords = "Aging, Antipsychotic, Dopamine, Elderly, Side effect",
author = "Hiroyuki Uchida and Mamo, {David C.}",
year = "2009",
month = "8",
day = "31",
doi = "10.1016/j.pnpbp.2009.04.023",
language = "English",
volume = "33",
pages = "917--920",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Dosing of antipsychotics in schizophrenia across the life-spectrum

AU - Uchida, Hiroyuki

AU - Mamo, David C.

PY - 2009/8/31

Y1 - 2009/8/31

N2 - Age effects on dosing of antipsychotics in schizophrenia and mechanisms underlying those effects have not been well understood. The objective of this article is to review the literature regarding effects of age on antipsychotic dosing in schizophrenia and potential mechanisms underlying the age-related antipsychotic sensitivity. According to prescription surveys, age appears to have biphasic effects on prescribed antipsychotic dose. The dose increased with age through the third decade, subsequently plateaued, and decreased after the fifth decade. The first half of this inverted U-shaped relationship may be attributable to a deterioration process in the early phase of schizophrenia and the contribution of 'tachyphylaxis' of antipsychotics on the dopaminergic system. The following age-related decline in prescribed dose is likely associated with physiological aging. Recent data suggest that this increased antipsychotic sensitivity with age comes from age-related functional decline in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Although the evidence on potential mechanisms underlying age effects on antipsychotic dosing is still limited, alterations in the dopaminergic system due to aging and chronic exposure to this drug may contribute to the inverted U-shaped relationship between dose and age. This age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients age to enhance therapeutic effects as well as minimize their side effects.

AB - Age effects on dosing of antipsychotics in schizophrenia and mechanisms underlying those effects have not been well understood. The objective of this article is to review the literature regarding effects of age on antipsychotic dosing in schizophrenia and potential mechanisms underlying the age-related antipsychotic sensitivity. According to prescription surveys, age appears to have biphasic effects on prescribed antipsychotic dose. The dose increased with age through the third decade, subsequently plateaued, and decreased after the fifth decade. The first half of this inverted U-shaped relationship may be attributable to a deterioration process in the early phase of schizophrenia and the contribution of 'tachyphylaxis' of antipsychotics on the dopaminergic system. The following age-related decline in prescribed dose is likely associated with physiological aging. Recent data suggest that this increased antipsychotic sensitivity with age comes from age-related functional decline in the dopaminergic system, including endogenous dopamine level and dopamine receptor density. Although the evidence on potential mechanisms underlying age effects on antipsychotic dosing is still limited, alterations in the dopaminergic system due to aging and chronic exposure to this drug may contribute to the inverted U-shaped relationship between dose and age. This age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients age to enhance therapeutic effects as well as minimize their side effects.

KW - Aging

KW - Antipsychotic

KW - Dopamine

KW - Elderly

KW - Side effect

UR - http://www.scopus.com/inward/record.url?scp=67651095785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651095785&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2009.04.023

DO - 10.1016/j.pnpbp.2009.04.023

M3 - Article

C2 - 19426777

AN - SCOPUS:67651095785

VL - 33

SP - 917

EP - 920

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 6

ER -